Investigational drug · Phase 3
SIM0811
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acute Ischemic Stroke AIS.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "SIM0811"
First trial start
2026
Nov 30, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SIM0811", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Ischemic Stroke AIS
Approved drugs for the same conditions: Stroke prevention · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "SIM0811" as an intervention, largest first.
- A Phase II/III Clinical Study of SIM0811 in the Treatment of Acute Ischemic StrokePivotal-lookingNot yet recruiting
Jiangsu Simcere Pharmaceutical Co., Ltd.Industry
NCT07903701 · 1,092 participants (planned) · Start Nov 30, 2026 · Primary completion Jun 30, 2029
Drug: SIM0811 Dose Level A (Phase II); SIM0811 Dose Level B (Phase II) and 4 more · For: Acute Ischemic Stroke AIS
Jiangsu Simcere Pharmaceutical Co., Ltd.Industry
NCT07345364 · 64 participants · Start Jan 12, 2026 · Primary completion Jun 18, 2026
Drug: SIM0811; Placebo · For: Health, Subjective
Sites: Jinan, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Acute Ischemic Stroke AIS
- hUC-MSCsmesenchymal stem cells, MSCPhase 38 trials
Shenzhen Wingor Biotechnology Co., Ltd. · Knee Osteoarthritis, Crohn&Amp;#39;s, Crohn&Amp;#39;s Disease (CD)
- Recombinant Human ProurokinaserhPro-UKPhase 31 trial
Tasly Biopharmaceuticals Co., Ltd. · Acute Ischemic Stroke AIS
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.